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ics. SAS version 9.2 was used for analyses of data. Descriptive statistics were obtained 
by using survey frequency procedures that accounted for survey design and weighting. 
Weighted analyses were performed using survey logistic procedure controlling for 
interactions amongst the independent variables. RESULTS: During the 2 year period 
from 2005 and 2006, 3500 patients representing 12,769,828 CAD patients were 
identiﬁed. A total of 340 CAD patients representing 1,229,496 patients underwent 
CT scan procedure. Observations with missing data were deleted as it constituted less 
than 1% of the total identiﬁed population. Following variables were found signiﬁ-
cantly associated with probability of getting a CT scan: Painlevel, EKG use, Physician 
seen, Physician assistant seen, Race/ethnicity and Mode of arrival. These variables 
do not act in isolation and interactions between them were considered in the analyses 
CONCLUSIONS: The use of CT scan as a diagnostic tool in CAD patients admitted 
in ED depends on a multitude of interdependent factors such as patient characteristics 
deﬁned by painlevel, race/ethnicity, provider characteristics or the type of provider 
seen and type of health service utilized such as ambulance and concurrent EKG use.
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OBJECTIVES: Better selection of ischemic stroke patients for intravenous recombi-
nant tissue plasminogen activator (IV tPA) treatment based on the penumbral hypoth-
esis as seen through magnetic resonance imaging (MRI) by may improve clinical 
outcomes. However given the limited availability of MRIs in hospitals, MRI-based 
methods may not be feasible. We examined the cost-effectiveness of adding perfusion 
imaging with computed tomography (CTP) to usual computed tomography (CT)-
based methods to examine presence and extent of penumbra such that patients can 
be identiﬁed for IV tPA treatment. METHODS: A decision-analytic model was devel-
oped to estimate costs and outcomes associated with selecting patients for IV tPA 
treatment via CTP compared to current usual care of selection based on CT scan and 
patient history from a hospital perspective. The patient population was similar to that 
observed in the IV tPA clinical trials included in a recent meta-analysis. Clinical data 
was derived from published clinical trials. Costs were obtained from standard US 
costing sources and utilities were obtained from published literature. All costs are 
presented in 2009 US dollars. Outcomes included cost per life-year saved and cost per 
quality-adjusted life-year (QALY) gained. Sensitivity analyses were conducted. 
RESULTS: From the hospital perspective, the addition of penumbral-based CTP selec-
tion improved favorable outcome (modiﬁed Rankin Scale ≤1) by 0.59% and reduced 
cost by $42 compared with usual CT-based selection at hospital discharge. Life years 
and QALYs improved which resulted in the addition of penumbral-based CTP selec-
tion in being cost-savings to hospitals. Multivariate sensitivity analysis predicted 
cost-effectiveness (≤$50,000 per QALY) in 89.2% of simulation runs. CONCLU-
SIONS: Given costs and the limited availability of MRI, penumbral-based CTP after 
routine CT is a cost effective alternative for hospitals in selecting ischemic stroke 
patients for IV tPA treatment.
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OBJECTIVES: The recent re-label of clopidogrel to include information on CYP2C19 
genotype and the approval of a second-generation antiplatelet medication, prasugrel, 
could greatly impact the way antiplatelet therapy is prescribed. This study assesses the 
cost-effectiveness of genotyping patients to guide selection of antiplatelet therapy with 
clopidogrel or prasugrel. METHODS: A decision tree was created using prevalence 
of CYP2C19 metabolism status, cardiovascular events, and bleeding events and costs 
of events as reported in the literature and publically available FDA advisory committee 
documents. In the genotype arm, an individual’s metabolic status determined medica-
tion selection. Effect was deﬁned as the cost per event avoided. Scenario analyses that 
were conducted to determine the robustness of the model included scenario A: clopi-
dogrel use without genotyping and scenario B: prasugrel use without genotyping. 
Number needed to genotype to avoid one cardiovascular or bleeding event from 
occurring was also determined. RESULTS: The probability of being an ultra-rapid or 
extensive metabolizer of CYP2C19 was 73% and the probability of being an inter-
mediate or poor metabolizer was 27%. For the no-genotype arm, the estimated pro-
portions of medication selection used were 70% to receive clopidogrel and 30% to 
receive prasugrel. The model favored the intervention of genotyping patients to deter-
mine antiplatelet therapy (ICER: −$20,049). Both scenario analyses exhibited a domi-
nant strategy of genotyping patients (ICERA: −$21,833 and ICERB: −$15,918). 
Number needed to genotype to avoid one bleeding or cardiovascular event was 26. 
CONCLUSIONS: The cost-effectiveness analysis suggests it is more effective and less 
costly to genotype patients prior to selecting clopidogrel or prasugrel for the patient’s 
antiplatelet therapy.
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OBJECTIVES: Patients who self-discharge against medical advice (AMA) may be at 
higher risk for a hospital readmission if the unauthorized discharge was premature. 
The study objective is to examine the relationship between discharges AMA and 
cardiovascular disease (CVD) hospital readmissions while addressing bias due to 
potential confounding, selection, and hospital-level clustering. METHODS: This 
cross-sectional study uses conﬁdential inpatient hospital discharge data covering the 
years 2000 to 2005. The outcome variables captured readmissions for a CVD-related 
condition following an index CVD-related admission. The covariate of interest was 
an indicator variable for a discharge AMA in the index hospitalization. The relation-
ship between discharges AMA and 7-day, 31-day, 180-day, and 365-day hospital 
readmissions was examined using generalized linear models with adjustments for 
clustering and selection bias. RESULTS: The sample included 443,088 patients, of 
which 22,757 (5.1%) were readmitted to the same hospital. Approximately 1% of 
the patients who were readmitted in the hospital during the study period left AMA 
on the index admission while 0.89% of those who were not readmitted left AMA (p 
= 0.047). The odds of a CVD-related readmission within 7 days, 31 days, 180 days 
and 365 days were 145% (p < 0.001), 55% (p < 0.001), 26% (p < 0.001) and 15% 
(p = 0.0011) higher for patients discharged AMA on index admission compared to 
those who were discharged formally. Results are robust to corrections for observable 
selection bias (via propensity score analysis) and hospital-level clustering. CONCLU-
SIONS: A self-discharge AMA among patients admitted for CVD is predictive of 
CVD-related readmissions and the strength of association increases as the time 
between admissions decreases.
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OBJECTIVES: Future reﬁnement of pharmacotherapy of atrial ﬁbrillation/atrial ﬂutter 
(AF) requires a detailed understanding of how treatments are currently employed in 
clinical practice. METHODS: In this retrospective cohort study, we used the US 
MarketScan® database to identify patients ≥18 years with AF (≥1 AF inpatient or ≥2 
outpatient AF claims) and ≥18 months’ continuous enrollment data between Jan 2003 
and Sept 2007. The ﬁrst qualifying AF diagnosis following 12 months’ enrollment was 
designated the index diagnosis. AF was classiﬁed as newly-diagnosed (ND) or pre-
existing (PRE), based on treatment history in the pre-index period. RESULTS: Of 
184,155 identiﬁed patients (mean age 73 years, 55% men), 64,669 had ND and 
119,486 had PRE AF. Non-pharmacotherapy for AF was undertaken in 11% of 
patients with ND vs 6% of patients with PRE disease, most commonly cardioversion 
(9% vs. 4% of patients, respectively). Across both patient groups, 30% received no 
drug therapy within 30 days of initial AF diagnosis (initial treatment), 17% received 
antiarrhythmics (rhythm-control agents), 51% rate-control agents, 40% anticoagu-
lants, and 5% antiplatelets (aspirin use was not captured). Median duration of uninter-
rupted initial therapy was 210 days for antiarrhythmics and antiplatelets, 228 days 
for anticoagulants and 420 days for rate-control agents. Over the entire post-index 
follow-up period (mean 20 months), ND and PRE AF patients received antiarrhyth-
mics (27% vs 28%), rate-control agents (77% vs 76%), anticoagulants (54% vs. 66%) 
and antiplatelets (14% vs. 10%). Overall, the most commonly used drugs were amio-
darone (15%), β-blockers (56%), calcium channel blockers (23%), cardiac glycosides 
(35%), warfarin (61%) and clopidogrel (11%). CONCLUSIONS: Non-pharmacolog-
ical interventions for AF were relatively uncommon. Almost one-third of AF patients 
in our study remained untreated for the ﬁrst 30 days after diagnosis, which may 
represent under-treatment. Rate-control agents and anticoagulants were used more 
frequently than antiarrhythmics and antiplatelets for treatment of AF.
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OBJECTIVES: Coincident with the increasing focus on comparative effectiveness 
research (CER), a number of organizations have begun to engage in prioritizing 
topics for CER. This paper presents the priority-setting process developed by the 
Center for Medical Technology Policy (CMTP) and its application to the selection 
of cardiac technologies. METHODS: We reviewed criteria and processes used by 
other organizations. We then developed a multi-stage process including, 1) horizon 
scanning; 2) topic nomination; 3) expert solicitation; 4) topic review and selection; 
5) criteria application and discussion by a expert workgroup, and 6) ﬁnal ranking 
of topics for varied research projects. After internally reﬁning a broad list to the 
top ten technologies, we convened an expert workgroup charged with ranking these 
top technologies using prospectively developed criteria. Experts were provided with 
a list of criteria and briefs summarizing clinical, economic, and ethical aspects of 
each technology. RESULTS: Topic nomination produced an initial list of approxi-
mately 40 technologies, which were narrowed to the top ten based on suitability 
for CMTP’s coverage with evidence development (CED) initiatives and guidelines 
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for designing CER studies projects. The expert working group ranked technologies 
according to suitability for both CED and the guideline projects. The top 3 technolo-
gies that emerged for CED were 1) pharmacogenetic guidance of warfarin dosing; 
2) catheter ablation for atrial ﬁbrillation; and 3) percutaneous aortic valve replace-
ment. For the guidelines, the ranking was 1) C-reactive protein tests; 2) genetic 
testing for heart disease; and 3) bioabsorbable stents. CONCLUSIONS: A prospec-
tively developed multi-step process focusing on technologies within a disease area 
may improve the process of prioritizing technologies for CER, offering more direct 
guidance to researchers and policy makers. Notably, CMTP is initiating a CED 
project and the advisory workgroup selected the warfarin dosing topic, indicating 
the success of the process in choosing a relevant technology.
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OBJECTIVES: To analyze the difference of in-stay hospitalization frequency between 
Congestive Heart Failure (CHF) patients who are on the recommended medication 
and those who are not. METHODS: We use the inpatient, outpatient and medication 
ﬁles from the Thomson Reuters MarketScan data records of 2000 and 2001. First, 
we extract patients with CHF from the inpatient and outpatient ﬁles using ICD9 codes. 
Next, we extract these patients from the medication ﬁles. Depending on the NYHA 
classiﬁcation, there is a recommended combination of medication a CHF patient 
should have. We use these medications to divide the patients into two groups. Then, 
we analyze the data using logistic regression, kernel density estimation and ANOVA. 
The preprocessing and the statistical analysis are done using SAS software. RESULTS: 
The analysis yields a statistically noteworthy difference in proportions of number of 
in- stay hospitalizations between people on the recommended treatment and those 
who are not. Also, there is signiﬁcant difference in length of stay for the two groups. 
CONCLUSIONS: Being on the recommended combination of medication has a sig-
niﬁcant impact on the health care outcome for CHF patients.
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OBJECTIVES: To examine the effect of an employer-sponsored, pharmacist-provided 
medication therapy management program (MTM) on clinical outcomes and process 
measures in patients with diabetes and hypertension METHODS: A prospective, 
intent-to-treat, pre-post longitudinal study. Patients were Lucas County employees and 
dependents with diabetes, hypertension, or both. The MTM services were provided 
by independent pharmacists in Northwest Ohio at seven sites. ADA and JNC-VII 
guidelines were used to design interventions and set patient goals. Data was analyzed 
using SPSS v17.0 for three groups—hypertension only, diabetics, and hypertensive 
diabetics. Wilcoxon signed-rank test was used to compare 2 time points and the 
Friedman test was used to compare readings at baseline, 6,12,and 18 months. 
RESULTS: Five hundred eighty six patients enrolled at baseline. The Hypertension 
only group mean systolic blood pressure (SBP) improved from 135.37 ± 18.85 to 
130.33 ± 18.35 (p = 0.057). Diastolic blood pressure (DBP) improved from 81.71 ± 
10.70 to 80.35 ± 11.12 (p = .386). Uncontrolled hypertensive patient’s SBP mean 
improved from 153.03 ± 12.37 to 138.91 ± 19.74 (p < 0.01). DBP improved from 
97.07 ± 5.71 to 85.6 ± 13.20 (p < 0.05). For hypertensive diabetic patients SBP 
improved from 134.59 ± 18.99 to 128.35 ± 18.55 (p = 0.20). DBP improved from 
81.52 ± 11.25 to 79.52 ± 12.08 (p = 0.75). Uncontrolled diabetic hypertensive patients 
SBP mean improved from 145.96 ± 13.83 to 135.29 ± 17.62 (p < 0.05). DBP improved 
from 87.51 ± 6.54 to 82.71 ± 11.92 (p = 0.439). For uncontrolled diabetic patients 
A1c improved signiﬁcantly from 8.02 ± 1.31 to 7.41 ± 0.99 (p < 0.001). Patients with 
controlled A1c at baseline were able to maintain control for the 18 months of partici-
pation in the study. Upon being advised by their pharmacists more patients visited 
their dentist, podiatrist, and ophthalmologist. CONCLUSIONS: Pharmacists were 
able to help patients maintain A1c and BP goals thereby preventing future complica-
tions and costs to the employer.
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OBJECTIVES: ACEI or ARB therapy in patients with diabetes has been shown to 
delay progression to renal failure. This study evaluated the impact of a mailing inter-
vention to health care providers aimed at optimizing ACEI or ARB therapy in patients 
with diabetes plus hypertension and/or nephropathy. METHODS: A retrospective 
cohort study was performed using pharmacy claims data from a large Medicare Part 
D plan to evaluate an intervention notifying providers of missing ACEI/ARB therapy 
for 28,348 patients with diabetes plus hypertension and/or nephropathy not qualifying 
for Medication Therapy Management services (Non-MTM). A control cohort of 
50,757 Non-MTM Medicare Part D patients with diabetes plus hypertension and/or 
nephropathy not receiving ACEI or ARB therapy during the 7-month identiﬁcation 
period was selected from an earlier timeframe to be compared to the intervention 
cohort. The primary outcome was the percentage of identiﬁed patients initiating ACEI 
or ARB therapy during the 4-month post-intervention period. Logistic regression was 
performed using a dependent variable of initiation vs. no initiation of ACEI or ARB 
therapy in the post-intervention period. Independent variables included age, gender, 
chronic disease score, and hypertension and nephropathy diagnoses. RESULTS: 
During the post-intervention period, the unadjusted proportion of those beginning 
ACEI or ARB therapy was 15.0% for the intervention group compared to 12.2% for 
the control group (p < 0.0001). After adjusting for baseline characteristics, intervened 
patients had greater odds of initiating ACEI or ARB therapy compared to control 
patients (OR 1.40; 95% CI 1.33–1.48). A limitation of the evaluation is that the 
identiﬁcation and measurement periods for the control group were in a different part 
of the year than the intervention cohort. CONCLUSIONS: Intervention in patients 
with diabetes plus hypertension and/or nephropathy via health care providers demon-
strated an increased likelihood of initiation of ACEI or ARB therapy compared to a 
control group.
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OBJECTIVES: In addition to elevated low-density lipoprotein cholesterol (LDL-C), 
studies have implicated decreased high-density lipoprotein cholesterol (HDL-C) and 
elevated triglycerides (TG) as independent modiﬁable risk factors for cardiovascular 
disease. This study determined the proportion of patients with a single lipid abnormal-
ity (SLA) versus mixed dyslipidemia and their respective treatments among a large 
sample of managed care patients. METHODS: A retrospective cohort study of adults 
with a complete lipid panel between 1/1/2005 and 12/31/2008 in a US national health 
plan with >10 million commercial and Medicare Advantage members was conducted. 
SLA was deﬁned as one of the following: high LDL-C based on NCEP ATP III guide-
lines, low HDL-C (<40 mg/dL), or high TG (≥200 mg/dL). Mixed dyslipidemia was 
deﬁned as having ≥2 of the lipid abnormalities. Proportion of patients with an SLA 
or mixed dyslipidemia and lipid-modifying therapy patterns were evaluated. 
RESULTS: A total of 247,322 patients had dyslipidemia in the 4-year observation 
period; 68% had an SLA and 32% had mixed dyslipidemia. Of patients with SLA, 
47% had elevated LDL-C, 32% had low HDL-C, and 21% had elevated TG. For 
patients with an SLA, only 29% received lipid-modifying therapy, with 71% of those 
receiving statin monotherapy. Of patients with mixed dyslipidemia, 42% had low 
HDL-C and high TG, 22% had high LDL-C and low HDL-C, 21% had high LDL-C 
and high TG, and 15% had all 3 abnormal lipid parameters. In the mixed dyslipidemia 
group, only 33% received lipid-modifying therapy, with 58% of those receiving statin 
monotherapy and 19% receiving multi-pill combination therapy. CONCLUSIONS: 
The lack of treatment and inadequate treatment observed in this real-world study 
indicates an unmet medical need in managing lipid levels among dyslipidemic patients, 
including patients with mixed dyslipidemia.
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OBJECTIVES: Both angiotensin-converting-enzyme inhibitors (ACEIs) and angioten-
sin receptor blockers (ARBs) have been widely used for treatment of hypertension, 
heart failure, diabetes mellitus and kidney disease. The purposes of this study were to 
describe the utilization, price and expenditure trends of ACEIs and ARBs and to assess 
market-share competition between ACEIs and ARBs. METHODS: A retrospective, 
descriptive time-series analysis was performed using the National Medicaid pharmacy 
claims database from 1991 to 2008. The quarterly prescription numbers and reim-
bursement amounts were calculated over time by summing data for individual drug 
products. The quarterly per-prescription reimbursement as a proxy for drug price was 
computed for all brands and generics of ACEIs and ARBs. The market shares were 
calculated based on both prescription numbers and Medicaid payments. RESULTS: 
The ACEI prescriptions increased from 4.8 million in 1991 to 16.5 million in 2004, 
then dropped to 2.3 million in 2008. Meanwhile, ARB prescriptions increased from 
0.03 million in 1995 to 7.5 million in 2004, then dropped to 2.1 million in 2008. 
Concurrently, annual expenditure for ACEIs increased from $179 million in 1991 to 
$593 million in 2002, and dropped to $64 million in 2008. Expenditure for ARBs 
increased from $1.3 million in 1995 to $515 million in 2005, and dropped to $174 
million in 2008. Market shares for generic ACEIs like captopril, lisinopril and enala-
pril increased rapidly. All brand-name prices for ARBs and ACEIs increased over time 
regardless of new branded or generic drug entry, while generic prices decreased over 
time. CONCLUSIONS: Dramatically increased utilization of both ACEIs and ARBs 
may be due to their wide therapeutic indications and efﬁcacy. A signiﬁcant drop in 
utilization from 2006–2008 was related to the introduction of Medicare Part D. 
Increased utilization of generic ACEIs was likely due to the Medicaid generic substitu-
tion policy and changes in prescribing patterns.
